GlassScriptPhysician profile
Alicia M Stem
NPI 1124330816
$5,023.92
in general payments reported to CMS, 2019-2025
33 companies · $551 in 2025
The $551 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $978 · 2022: $765 · 2023: $1,492 · 2024: $1,238 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,280 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,279.91 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $706.08 | 2021-2025 | Leqvio |
| Merck Sharp & Dohme LLC | $642.18 | 2021-2025 | Verquvo |
| Abbott Laboratories | $361.81 | 2021-2025 | Ensite Precision, Ultreon, Quadra Allure Mp |
| Pfizer INC. | $361.31 | 2021-2025 | |
| Boston Scientific Corporation | $260.83 | 2022-2024 | Latitude Communicator Power Supply |
| E.R. Squibb & Sons, L.L.C. | $242.43 | 2021-2024 | Camzyos, Eliquis |
| Medtronic, INC. | $241.74 | 2024-2025 | Micra, Azure Xt Dr Mri Surescan |
| Novo Nordisk INC | $235.19 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Alnylam Pharmaceuticals INC. | $223.67 | 2021-2025 | Amvuttra, Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $211.49 | 2021-2023 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $207.19 | 2021-2023 | Farxiga |
| Amgen INC. | $197.90 | 2021-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $172.26 | 2023 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.32 | 2021-2023 | Jardiance |
| Daiichi Sankyo INC. | $112.07 | 2023 | Injectafer |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $99.68 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $92.17 | 2021-2022 | |
| Abiomed | $88.09 | 2023 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $76.46 | 2024 | |
| Esperion Therapeutics, INC. | $65.56 | 2021 | |
| Cvrx, INC. | $36.28 | 2024 | Barostim Neo System |
| Exact Sciences Corporation | $24.87 | 2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $22.50 | 2024 | Inspire |
| Lilly USA, LLC | $21.44 | 2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $21.28 | 2023 | |
| Azurity Pharmaceuticals, INC. | $19.94 | 2025 | Edarbyclor |
| Astellas Pharma US INC | $19.70 | 2021 | |
| Baxter Healthcare | $18.30 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Scpharmaceuticals INC. | $18.01 | 2025 | |
| Arbor Pharmaceuticals, INC. | $16.66 | 2021 | |
| Heartflow, INC. | $14.89 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $13.49 | 2023 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicia Stem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.